<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01377051</url>
  </required_header>
  <id_info>
    <org_study_id>654CEC</org_study_id>
    <nct_id>NCT01377051</nct_id>
  </id_info>
  <brief_title>Effect of Indacaterol Maleate in Chronic Obstructive Pulmonary Disease (COPD) on Lung Volume and Related Dyspnea</brief_title>
  <official_title>Acute Effect of Indacaterol Maleate on Static and Dynamic Lung Volume in COPD Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione Salvatore Maugeri</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Milan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether indacaterol maleate 300 micrograms (mcg) is
      effective in the acute treatment of COPD and in particular on reducing lung hyperinflation
      and dynamic volumes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolled patients: COPD of any disease severity in stable conditions. 48 hours of inhalatory
      drugs wash out.

      Evaluation: Plethysmographic test, blood gas analysis, blood pressure, cardiac frequency and
      Borg scale evaluation in basal condition and after 60 minutes of indacaterol maleate 300 mcg
      inhalation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intra Thoracic Gas Volume (ITGV)</measure>
    <time_frame>60 minutes after drug inhalation</time_frame>
    <description>A complete body plethysmografic test will be performed after indacaterol inhalation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Expired Volume in the first second (FEV1)</measure>
    <time_frame>60 minutes after drug inhalation</time_frame>
    <description>Will be performed: spirometry, Arterial blood sample, measurement of blood pressure and cardiac frequency. All these parameters will be tested 60 minutes after inhalation of Indacaterol 300 micrograms (mcg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial pressure of arterial oxygen (PaO2)</measure>
    <time_frame>60 minutes after drug inhalation</time_frame>
    <description>Arterial gas analysis will be performed evaluating all arterial gases</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>COPD</condition>
  <condition>Lung Diseases</condition>
  <condition>Dyspnea</condition>
  <condition>Hypoxemia</condition>
  <condition>Tachycardia</condition>
  <arm_group>
    <arm_group_label>Bronchodilator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Indacaterol maleate 300 mcg will be administered by a third independent investigator following a randomization list.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Will be administered with the same device by a third independent investigator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacaterol maleate</intervention_name>
    <description>Dry powered, 300 mcg, only one inhalation with 24 hours duration</description>
    <arm_group_label>Bronchodilator</arm_group_label>
    <other_name>Onbrez, Hirobriz, Onbrize, Oslif Breezehaler, Arcapta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dry powered, same to study drug, only one inhalation</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signature of consensus

          -  COPD diagnosis

          -  Age from 50 to 85 years old

          -  history of COPD at least of one year

          -  respiratory stable conditions at least of one month

          -  Any basal FEV1 expressed in % of predicted value

          -  FEV1/ Forced Vital Capacity (FVC) less than 70%

          -  Former or active smokers with at least a smoking history of 20 pack year

        Exclusion Criteria:

          -  Pregnancy

          -  FEV1/FVC more than 70%

          -  Known deficit of alpha 1 antitrypsin

          -  Subjects submitted to a Lung Volume Reduction Surgery (LVRS)

          -  Subjects with known positivity to Human Immunodeficiency Virus (HIV)

          -  Misuse of alcool or drugs

          -  Absence of compliance in performing respiratory tests
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierachille Santus, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universit√† degli Studi di Milano-Pneumologia Riabilitativa- Fondazione Maugeri-Istituto Scientifico di Milano-IRCCS - pierachille.santus@unimi.it</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pneumologia Riabilitativa - Fondazione Maugeri - Istituto Scientifico di Milano - IRCCS</name>
      <address>
        <city>Milano</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2011</study_first_submitted>
  <study_first_submitted_qc>June 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2011</study_first_posted>
  <last_update_submitted>October 28, 2014</last_update_submitted>
  <last_update_submitted_qc>October 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Milan</investigator_affiliation>
    <investigator_full_name>Pierachille Santus</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Inspiratory capacity</keyword>
  <keyword>Residual volume</keyword>
  <keyword>Total lung resistance</keyword>
  <keyword>Arterial Oxygen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

